BeOne Medicines (ONC) Non-Current Deffered Revenue (2017 - 2023)

BeOne Medicines (ONC) has reported Non-Current Deffered Revenue for 6 consecutive years, with $300000.0 the latest figure, recorded in Q4 2023.

• On a quarterly basis, Non-Current Deffered Revenue fell 99.29% year-over-year to $300000.0 in Q4 2023; TTM through Dec 2023 was $300000.0, a 99.29% decrease from a year earlier, with the FY2023 full-year figure at $300000.0, down 99.29% from the prior year.
• Non-Current Deffered Revenue was $300000.0 for Q4 2023 at BeOne Medicines, roughly flat from $300000.0 in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $220.3 million in Q4 2021 and troughed at $300000.0 in Q3 2023.
• A 4-year average of $81.6 million and a median of $52.3 million in 2021 frame the typical range for Non-Current Deffered Revenue.
• Across the five-year window, Non-Current Deffered Revenue surged 186.77% in 2022 and slumped 99.8% in 2023, its largest moves.
• Over 4 years, Non-Current Deffered Revenue stood at $8.2 million in 2019, then surged by 2573.41% to $220.3 million in 2021, then slumped by 80.92% to $42.0 million in 2022, then sank by 99.29% to $300000.0 in 2023.
• The last three Non-Current Deffered Revenue figures came in at $300000.0 (Q4 2023), $300000.0 (Q3 2023), and $24.3 million (Q2 2023), per Business Quant data.